Go Ad-Free
logoThe People's Perspective on Medicine

Antidepressant Pulled Off Market

The FDA has taken the unprecedented step of making a manufacturer withdraw its generic antidepressant from the market. Budeprion XL 300 was a branded generic that was introduced in 2006 after the antidepressant Wellbutrin XL 300 lost its patent. Many consumer complaints led the FDA to investigate the bioequivalence of this product. The FDA study revealed that the generic drug did not get into the bloodstream in an identical manner to the brand name drug. As a result, they concluded that Budeprion XL 300 was not bioequivalent to Wellbutrin XL 300 and should not be marketed. Other manufacturers of long acting bupropion, the generic compound in Wellbutrin, are being asked to test their formulations for bioequivalence. They will have to submit the data on their products to the FDA no later than March, 2013.

Rate this article
star-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-empty
4.5- 2 ratings
About the Author
Joe Graedon is a pharmacologist who has dedicated his career to making drug information understandable to consumers. His best-selling book, The People’s Pharmacy, was published in 1976 and led to a syndicated newspaper column, syndicated public radio show and web site. In 2006, Long Island University awarded him an honorary doctorate as “one of the country's leading drug experts for the consumer.”.
Tired of the ads on our website?

Now you can browse our website completely ad-free for just $5 / month. Stay up to date on breaking health news and support our work without the distraction of advertisements.

Browse our website ad-free
Join over 150,000 Subscribers at The People's Pharmacy

We're empowering you to make wise decisions about your own health, by providing you with essential health information about both medical and alternative treatment options.